Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

Science

Volumn 276, Issue 5314, 1997, Pages 955-960

  Mohammadi, Moosa ^a   McMahon, Gerald ^b   Sun, Li ^b   Tang, Cho ^b   Hirth, Peter ^b   Yeh, Brian K ^a   Hubbard, Stevan R ^c   Schlessinger, Joseph ^a  

^a NEW YORK UNIVERSITY   (United States)

^b SUGEN INC   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ARTICLE; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HYDROGEN BONDING; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; PHOSPHOTYROSINE; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, INSULIN; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 0030945871     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.276.5314.955     Document Type: Article

References (58)

1. J. M. Bishop, Science 235, 305 (1987); A. Ullrich and J. Schlessinger, Cell 61, 203 (1990); S. A. Aaronson, Science 254, 1146 (1991).
2. J. M. Bishop, Science 235, 305 (1987); A. Ullrich and J. Schlessinger, Cell 61, 203 (1990); S. A. Aaronson, Science 254, 1146 (1991).
3. J. M. Bishop, Science 235, 305 (1987); A. Ullrich and J. Schlessinger, Cell 61, 203 (1990); S. A. Aaronson, Science 254, 1146 (1991).
4. A. Levitzki and A. Gazit, Science 267, 1782 (1995).
5. C. Basilico and D. Moscatelli, Adv. Cancer Res. 59, 115 (1992).
6. M. Jaye, J. Schlessinger, C. Dionne, Biochim. Biophys. Acta 1135, 185 (1992).
7. W. Reardon et al., Nature Genet. 8, 98 (1994); K. M. Neilson and R. E. Friesel, J. Biol Chem. 270, 26037 (1995).
8. W. Reardon et al., Nature Genet. 8, 98 (1994); K. M. Neilson and R. E. Friesel, J. Biol Chem. 270, 26037 (1995).
9. R. Shiang et al., Cell 78, 335 (1994); F. Rousseau et al., Nature 371, 252 (1994); M. K. Webster and D. J. Donoghue, EMBO J. 15, 520 (1996).
10. R. Shiang et al., Cell 78, 335 (1994); F. Rousseau et al., Nature 371, 252 (1994); M. K. Webster and D. J. Donoghue, EMBO J. 15, 520 (1996).
11. R. Shiang et al., Cell 78, 335 (1994); F. Rousseau et al., Nature 371, 252 (1994); M. K. Webster and D. J. Donoghue, EMBO J. 15, 520 (1996).
12. M. C. Naski et al., Nature Genet. 13, 233 (1996).
13. P. L. Tavormina et al., ibid. 9, 321 (1995); M. K. Webster et al., Mol. Cell. Biol. 16, 4081 (1996).
14. P. L. Tavormina et al., ibid. 9, 321 (1995); M. K. Webster et al., Mol. Cell. Biol. 16, 4081 (1996).
15. M. Klagsbrun and E. R. Edelman, Arteriosclerosis 9, 269 (1989); H. Brem and M. Klagsbrun, in Oncogenes and Tumor Suppressor Genes in Human Malignancies, C. C. Benz and E. T. Liu, Eds. (Kluwer Academic, Boston, 1993), p. 211; M. Klagsbrun and P. A. D'Amore, Ann. Rev. Physiol. 53, 217 (1991).
16. M. Klagsbrun and E. R. Edelman, Arteriosclerosis 9, 269 (1989); H. Brem and M. Klagsbrun, in Oncogenes and Tumor Suppressor Genes in Human Malignancies, C. C. Benz and E. T. Liu, Eds. (Kluwer Academic, Boston, 1993), p. 211; M. Klagsbrun and P. A. D'Amore, Ann. Rev. Physiol. 53, 217 (1991).
17. M. Klagsbrun and E. R. Edelman, Arteriosclerosis 9, 269 (1989); H. Brem and M. Klagsbrun, in Oncogenes and Tumor Suppressor Genes in Human Malignancies, C. C. Benz and E. T. Liu, Eds. (Kluwer Academic, Boston, 1993), p. 211; M. Klagsbrun and P. A. D'Amore, Ann. Rev. Physiol. 53, 217 (1991).
18. J. Adnane et al., Oncogene 6, 659 (1991); F. Penault-Llorca et al., Int. J. Cancer 61,170 (1995); J. Jacquemier et al., ibid. 59, 373 (1994); S. W. McLeskey, I. Y. Ding, M. E. Uppman, F. G. Kem, Cancer Res. 54, 523 (1994); Y. A. Luqmani ef al., Int. J. Cancer 64, 274 (1995); S. Jaakkola et al., ibid. 54, 374 (1993).
19. J. Adnane et al., Oncogene 6, 659 (1991); F. Penault-Llorca et al., Int. J. Cancer 61,170 (1995); J. Jacquemier et al., ibid. 59, 373 (1994); S. W. McLeskey, I. Y. Ding, M. E. Uppman, F. G. Kem, Cancer Res. 54, 523 (1994); Y. A. Luqmani ef al., Int. J. Cancer 64, 274 (1995); S. Jaakkola et al., ibid. 54, 374 (1993).
20. J. Adnane et al., Oncogene 6, 659 (1991); F. Penault-Llorca et al., Int. J. Cancer 61,170 (1995); J. Jacquemier et al., ibid. 59, 373 (1994); S. W. McLeskey, I. Y. Ding, M. E. Uppman, F. G. Kem, Cancer Res. 54, 523 (1994); Y. A. Luqmani ef al., Int. J. Cancer 64, 274 (1995); S. Jaakkola et al., ibid. 54, 374 (1993).
21. J. Adnane et al., Oncogene 6, 659 (1991); F. Penault-Llorca et al., Int. J. Cancer 61,170 (1995); J. Jacquemier et al., ibid. 59, 373 (1994); S. W. McLeskey, I. Y. Ding, M. E. Uppman, F. G. Kem, Cancer Res. 54, 523 (1994); Y. A. Luqmani ef al., Int. J. Cancer 64, 274 (1995); S. Jaakkola et al., ibid. 54, 374 (1993).
22. J. Adnane et al., Oncogene 6, 659 (1991); F. Penault-Llorca et al., Int. J. Cancer 61,170 (1995); J. Jacquemier et al., ibid. 59, 373 (1994); S. W. McLeskey, I. Y. Ding, M. E. Uppman, F. G. Kem, Cancer Res. 54, 523 (1994); Y. A. Luqmani ef al., Int. J. Cancer 64, 274 (1995); S. Jaakkola et al., ibid. 54, 374 (1993).
23. J. Adnane et al., Oncogene 6, 659 (1991); F. Penault-Llorca et al., Int. J. Cancer 61,170 (1995); J. Jacquemier et al., ibid. 59, 373 (1994); S. W. McLeskey, I. Y. Ding, M. E. Uppman, F. G. Kem, Cancer Res. 54, 523 (1994); Y. A. Luqmani ef al., Int. J. Cancer 64, 274 (1995); S. Jaakkola et al., ibid. 54, 374 (1993).
24. H. Y. Leung, W. J. Gullick, N. R. Lemoine, Int. J. Cancer 59, 667 (1994).
25. F. Yamaguchi, H. Saya, J. M. Bruner, R. S. Morrison, Proc. Natl. Acad. Sci. U.S.A. 91, 484 (1994); R. S. Morrison ef al., J. Neurooncol. 18, 207 (1994).
26. F. Yamaguchi, H. Saya, J. M. Bruner, R. S. Morrison, Proc. Natl. Acad. Sci. U.S.A. 91, 484 (1994); R. S. Morrison ef al., J. Neurooncol. 18, 207 (1994).
27. Y. Myoken et al., Int. J. Cancer 65, 650 (1996).
28. J. J. Li et al., Cancer 72, 2253 (1993).
29. C. Theillet et al., Genes Chromosomes Cancer 7, 219 (1993).
30. M. T. Story, World J. Urol. 13, 297 (1995); J. L. Ware, Cancer Metastasis Rev. 12, 287 (1993).
31. M. T. Story, World J. Urol. 13, 297 (1995); J. L. Ware, Cancer Metastasis Rev. 12, 287 (1993).
32. Preparation of 3-[4-(1-formylpiperazin-4-yl)benzylidenyl]-2-indolinone (SU4984) was as follows: A reaction mixture of 133.15 mg (1.0 mmol) of oxindole, 228.3 mg (1.2 mmol) of 4-(1-formylpiperazin-4-yl)benzaldehyde, and three drops of piperidine in 2 ml of ethanol was stirred at 90°C for 5 hours. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 199.5 mg (65%) of SU4984 as a yellow solid. Nuclear magnetic resonance (NMR) spectroscopy showed that SU4984 exists predominantly in the frans configuration (C-2, C-1 ′), although in the crystal structure, SU4984 is observed in the cis configuration. Preparation of 3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone (SU5402) was as follows: A reaction mixture of 134.0 mg (1.0 mmol) of oxindole, 217.43 mg (1.2 mmol) of 3-(2-carboxyethyl)-4-methylpyrrol-2-carboxaldehyde, and three drops of piperidine in 3 ml of ethanol was stirred at 90°C for 3 hours. After cooling, the precipitate was filtered, washed with cold ethanol, and dried to yield 172.4 mg (58%) of SU5402 as a yellow solid. NMR spectroscopy showed that SU5402 exists predominantly in the cis configuration.
33. 32P incorporation was quantitated by Cerenkov counting with a β counter.
34. NIH 3T3 cells expressing endogenous FGF receptors were used. Cell culture, cell lysis, immunoprecipitation, and immunoblotting were carried out according to standard procedures. Anti-FGFR1 was described previously [M. Mohammadi ef al., Mol. Cell. Biol. 16, 977 (1996)].
35. 3H]Thymidine incorporation was done as described by Mohammadi et al. (19).
36. NIH 3T3 cells expressing endogenous PDGF receptors were used. Also used were HER14 cells (33) and NIHIR cells [S. J. lsakoff et al., J. Biol. Chem. 271, 3959 (1996)]. The EGF receptor was immunoprecipitated with monoclonal antibody 108 (33), insulin receptor with monoclonal antibodies (BBE) [N. P. Moller et al., J. Biol. Chem. 270, 23126 (1995)], and PDGF receptor with polyclonal antibodies (PR4) [S, Mori et al., EMBO J. 12, 2257 (1993)].
37. NIH 3T3 cells expressing endogenous PDGF receptors were used. Also used were HER14 cells (33) and NIHIR cells [S. J. lsakoff et al., J. Biol. Chem. 271, 3959 (1996)]. The EGF receptor was immunoprecipitated with monoclonal antibody 108 (33), insulin receptor with monoclonal antibodies (BBE) [N. P. Moller et al., J. Biol. Chem. 270, 23126 (1995)], and PDGF receptor with polyclonal antibodies (PR4) [S, Mori et al., EMBO J. 12, 2257 (1993)].
38. NIH 3T3 cells expressing endogenous PDGF receptors were used. Also used were HER14 cells (33) and NIHIR cells [S. J. lsakoff et al., J. Biol. Chem. 271, 3959 (1996)]. The EGF receptor was immunoprecipitated with monoclonal antibody 108 (33), insulin receptor with monoclonal antibodies (BBE) [N. P. Moller et al., J. Biol. Chem. 270, 23126 (1995)], and PDGF receptor with polyclonal antibodies (PR4) [S, Mori et al., EMBO J. 12, 2257 (1993)].
39. M. Mohammadi, J. Schlessinger, S. R. Hubbard, Cell 86, 577 (1996).
40. S. S. Taylor and E. Radzio-Andzelm, Structure 2, 345 (1994).
41. K. A. Thomas, G. M. Smith, T. B. Thomas, R. J. Feldman, Proc. Natl Acad. Sci. U.S.A. 79, 4843 (1982).
42. G. McMahon, unpublished results.
43. S. R. Hubbard, in preparation.
44. _, L. Wei, L. Ellis, W. A. Hendrickson, Nature 372, 746 (1994).
45. R. M. Lyall et al., J. Biol. Chem. 264, 14503 (1989); B. Margolis et al., Cell 57, 1101 (1989).
46. R. M. Lyall et al., J. Biol. Chem. 264, 14503 (1989); B. Margolis et al., Cell 57, 1101 (1989).
47. W. F. De Azevedo et al., Proc. Natl. Acad. Sci. U.S.A. 93, 2735 (1996); U. Schulze-Gahmen et al., Proteins Struct. Funct. Genet. 22, 378 (1995).
48. W. F. De Azevedo et al., Proc. Natl. Acad. Sci. U.S.A. 93, 2735 (1996); U. Schulze-Gahmen et al., Proteins Struct. Funct. Genet. 22, 378 (1995).
49. R.-M. Xu, G. Carmel, J. Kuret, X. Cheng, Proc. Natl. Acad. Sci. U.S.A. 93, 6308 (1996).
50. R. A. Engh, A. Girod, V. Kinzel, R. Huber, D. Bossemeyer, J. Biol. Chem. 271, 26157 (1996).
51. M. G. Malkin, W. P. Mason, F. S. Lieberman, L. K. Shawver, A, L. Hannah, in Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology, Philadelphia, PA, 18 to 21 May 1996 (American Society of Clinical Oncology, Philadelphia, PA, 1996), vol. 15, p. 1573.
52. A. M. Honegger et al., Cell 51, 199 (1987).
53. S. V. Evans, J. Mol. Graphics 11, 134 (1993).
54. A. Nicholls, K. A. Sharp, B. Honig, Proteins 11, 281 (1991).
55. Z. Otwinowski, in Data Collection and Processing, L. Sawyer, N. Isaacs, S. Bailey, Eds. (SERC Daresbury Laboratory, Warrington, UK, 1993), p. 56.
56. A. T. Brünger, X-PLOR Version 3.1: A System for X-ray and NMR (Yale Univ. Press, New Haven, CT, 1992).
57. T. A. Jones, Methods Enzymol. 115, 157 (1985).
58. Equipment in the structural biology program at the Skirball Institute is partially supported by a grant from the Kresge Foundation. Coordinates have been deposited in the Brookhaven Protein Data Bank, entries 1FGI and 1AGW.